Search Results
Aug 07, 2026, 07:30 ET Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an
More news about: SOLIGENIX, INC.
Jun 08, 2026, 07:30 ET Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
May 26, 2026, 07:30 ET Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
May 08, 2026, 07:30 ET Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Apr 28, 2026, 07:30 ET Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Apr 02, 2026, 07:30 ET Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Mar 31, 2026, 07:30 ET Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Mar 26, 2026, 07:30 ET Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: Soligenix
Mar 19, 2026, 07:30 ET Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Mar 10, 2026, 07:30 ET Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Feb 26, 2026, 07:30 ET Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Feb 24, 2026, 07:30 ET Soligenix to Present at BIO Investment & Growth Summit
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Feb 12, 2026, 07:30 ET Soligenix Details Recent Progress and Upcoming Milestones
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Dec 18, 2025, 07:30 ET Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
therapyPRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Dec 17, 2025, 07:30 ET Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
PRINCETON, N.J., Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Nov 19, 2025, 07:30 ET Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Nov 07, 2025, 07:30 ET Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Oct 14, 2025, 07:30 ET Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: Soligenix
Oct 07, 2025, 07:30 ET Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Sep 30, 2025, 07:30 ET Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.
Sep 29, 2025, 16:05 ET Soligenix Announces Closing of $7.5 Million Public Offering
Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where
More news about: SOLIGENIX, INC.
Sep 26, 2025, 06:33 ET Soligenix Announces Pricing of $7.5 Million Public Offering
Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where
More news about: SOLIGENIX, INC.
Sep 23, 2025, 07:30 ET Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there
More news about: SOLIGENIX, INC.